GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment.

Saved in:
Bibliographic Details
Title: GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment.
Authors: Nuermberger EL; Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins Universitygrid.21107.35grid.471401.7grid.21107.35 School of Medicine, Baltimore, Maryland, USA., Martínez-Martínez MS; Diseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain., Sanz O; Diseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain., Urones B; Diseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain., Esquivias J; Diseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain., Soni H; Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins Universitygrid.21107.35grid.471401.7grid.21107.35 School of Medicine, Baltimore, Maryland, USA., Tasneen R; Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins Universitygrid.21107.35grid.471401.7grid.21107.35 School of Medicine, Baltimore, Maryland, USA., Tyagi S; Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins Universitygrid.21107.35grid.471401.7grid.21107.35 School of Medicine, Baltimore, Maryland, USA., Li SY; Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins Universitygrid.21107.35grid.471401.7grid.21107.35 School of Medicine, Baltimore, Maryland, USA., Converse PJ; Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins Universitygrid.21107.35grid.471401.7grid.21107.35 School of Medicine, Baltimore, Maryland, USA., Boshoff HI; Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Robertson GT; Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA., Besra GS; Institute of Microbiology and Infection, School of Biosciences, University of Birminghamgrid.6572.6, Birmingham, United Kingdom., Abrahams KA; Institute of Microbiology and Infection, School of Biosciences, University of Birminghamgrid.6572.6, Birmingham, United Kingdom., Upton AM; TB Alliance: Global Alliance for Tuberculosis Drug Development, New York, New York, USA., Mdluli K; TB Alliance: Global Alliance for Tuberculosis Drug Development, New York, New York, USA., Boyle GW; GSK: Research, GlaxoSmithKline R&D, Ware, United Kingdom., Turner S; GSK: Research, GlaxoSmithKline R&D, Ware, United Kingdom., Fotouhi N; TB Alliance: Global Alliance for Tuberculosis Drug Development, New York, New York, USA., Cammack NC; Diseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain., Siles JM; Diseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain., Alonso M; Diseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain., Escribano J; Diseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain., Lelievre J; Diseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain., Rullas-Trincado J; Diseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain., Pérez-Herrán E; Diseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain., Bates RH; Diseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain., Maher-Edwards G; GSK, Brentford, Middlesex, United Kingdom., Barros D; Diseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain., Ballell L; Diseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain., Jiménez E; Diseases of the Developing World, GlaxoSmithKline R+D Limited, Tres Cantos, Madrid, Spain.
Source: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2022 Jun 21; Vol. 66 (6), pp. e0013222. Date of Electronic Publication: 2022 May 24.
Publication Type: Journal Article; Research Support, N.I.H., Intramural
Journal Info: Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-6596 (Electronic) Linking ISSN: 00664804 NLM ISO Abbreviation: Antimicrob Agents Chemother Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1098-6596
DOI:10.1128/aac.00132-22